Glass House Brands (GLAS) Gross Margin (2020 - 2026)

Glass House Brands (GLAS) posted quarterly Gross Margin of 24.72% for Q1 2026, down 27.26% quarter-over-quarter from 33.99% in Q4 2025.

Glass House Brands (GLAS) Gross Margin (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported Gross Margin for 7 consecutive years, with 24.72% the latest figure, recorded in Q1 2026.

In Q1 2026, Gross Margin changed N/A year-over-year to 24.72%; the TTM figure through Mar 2026 stood at 37.66% (changed N/A YoY), while the FY2025 annual figure was 42.29%, down 619.0% from the prior year.
Gross Margin declined to 24.72% in Q1 2026 per GLAS's latest filing, from 33.99% in the prior quarter.
Across five years, Gross Margin topped out at 54.57% in Q2 2023 and bottomed at 1.54% in Q2 2022.
Historically, Gross Margin has averaged 33.03% across 5 years, with a median of 30.85% in 2022.
Annual changes were most pronounced in 2022 — Gross Margin plunged 4448 bps — and 2023, when it surged 5302 bps.
Glass House Brands' Gross Margin stood at 30.83% in 2022, then soared by 77 bps to 54.57% in 2023, then declined by 3 bps to 53.16% in 2024, then sank by 36 bps to 33.99% in 2025, then fell by 27 bps to 24.72% in 2026.
Business Quant data shows GLAS's Gross Margin at 24.72% in Q1 2026, 33.99% in Q4 2025, and 30.58% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-	-
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn	51.98%
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	42.63%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	66.66%
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn	87.30%
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn	38.77%
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	97.58%
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	58.33%
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Glass House Brands	830.21 Mn	811.66 Mn	15.77 Mn	33.54%

Download Data